Dumbo Health launches sleep membership tied to biomarkers and care
The new Sleep Longevity service connects wearable data, blood markers, physician review and at-home testing to treatment pathways for sleep disorders.
By Priya Raghavan · Science Reporter
3 min read
Dumbo Health has launched Sleep Longevity, a consumer-health membership that aims to connect sleep tracking with clinical care. The service is built for people who collect sleep data from wearables but may need testing, physician review or treatment for conditions such as sleep apnea.
The membership centers on a metric Dumbo Health calls SleepLongevityAge, which combines 51 sleep-focused blood biomarkers with wearable data when available, reported symptoms and a physician’s interpretation. The company says the score is meant to show how a member’s sleep may be affecting long-term health, rather than only summarize a single night of rest.
Consumer sleep technology has made scores and dashboards common, but those tools often sit outside the medical system. Sleep apnea care, meanwhile, can require referrals, lab studies and separate providers, creating delays for patients who need diagnosis and treatment.
Sleep Longevity is designed to put prevention, diagnostic testing and treatment into one membership. If the company’s review flags elevated risk, members can be routed to at-home sleep apnea testing, physician-reviewed diagnosis, CPAP therapy, mask fitting, adherence coaching and follow-up care through the same platform.
Dumbo Health said physician-reviewed diagnoses can be returned in as little as 48 hours and treatment can begin in as little as seven days. Its sleep apnea care is currently available in Florida, Texas, Virginia and Maryland, with national expansion planned; the broader Sleep Longevity membership is offered nationwide.
“We don’t believe the future of healthcare is more dashboards,” said Nicolas Nemeth, co-founder of Dumbo Health. “The future is knowing what to do next. Wearables measure sleep. Dumbo Health helps you improve it.”
The company was founded after co-founder Mohamed Haouache was diagnosed with sleep apnea and encountered months of referrals, sleep-lab waits and disconnected care. “I was handed a device and left to figure it out alone,” Haouache said. “That is exactly the experience Dumbo Health was built to end.”
Dumbo Health is using sleep apnea as its first clinical pathway. The company cited estimates that about 80% of obstructive sleep apnea goes undiagnosed and that roughly 90% of women with sleep apnea are not diagnosed, in part because symptoms may appear as fatigue, anxiety, brain fog or insomnia rather than loud snoring.
The service comes in two annual membership tiers. One includes the 51-marker sleep panel, SleepLongevityAge, physician interpretation, wearable integration and a personalized sleep plan. A higher-touch tier adds a broader 103-marker panel, a personal sleep coach, a private physician and additional testing.
The company’s scientific committee includes Dr. Alon Avidan of UCLA, Dr. Meir Kryger of Yale, Dr. Guy Leschziner of King’s College London, Dr. Guillaume Marchand and Olivier Véran, a physician and former French health minister.
Dumbo Health says its longer-term plan is to extend the platform beyond sleep apnea into insomnia, women’s sleep health, pediatric sleep, metabolic health, cardiovascular prevention, Alzheimer’s risk, employer benefits and AI-supported sleep care. For now, the Sleep Longevity membership for sleep care marks its push to turn sleep scores and lab data into a medical pathway.